載入...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science (PLoS)
2018-01-01
|
| 叢編: | PLoS ONE |
| 在線閱讀: | http://europepmc.org/articles/PMC5976165?pdf=render |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|